In addition to the NETTER1 trial presented at the European Cancer Congress, two other phase 3 NET clinical trials presented their results.
Everolimus conferred a statistically significant and clinically meaningful PFS benefit with an acceptable safety profile in patients with advanced, progressive neuroendocrine tumors of the lung or gastrointestinal region, according to phase 3 trial results (Radiant4).
"This is the first randomized clinical trial to show any benefit in lung NETs," James C. Yao, MD, professor in the department of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, "There is no other treatment available for those patients. Outside the pancreatic area, there is really no approved treatment that shows any benefit for progressive NETs." To read more about this study click here.
The phase 3 results from the Telestar were also presented. "Telotristat etiprate represents a novel approach by specifically inhibiting serotonin synthesis and, as such, is a promising potential new treatment for patients whose lives can be significantly impacted by this debilitating condition," lead investigator Matthew H. Kulke, MD, director, Program in Neuroendocrine and Carcinoid Tumors, Dana-Farber Cancer Institute, said in a statement. "These results are exciting from both an efficacy and safety perspective for carcinoid syndrome patients." To read more click here.